UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 8-K


CURRENT REPORT


Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported) September 28, 2018


NUTRA PHARMA CORP.

(Exact name of registrant as specified in its charter)


California

 

000-32141

 

91-2021600

(State or other jurisdiction
of incorporation)

 

(Commission File Number)

 

(IRS Employer
Identification No.)


12538 West Atlantic Blvd
Coral Springs, Florida

 

33071

(Address of principal executive offices)

 

(Zip Code)


Registrant’s telephone number, including area code: (954) 509-0911


Not Applicable

(Former name or former address, if changed since last report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging Growth Company ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨




ITEM 7.01     Regulation FD Disclosure.


On September 28, 2018, Nutra Pharma Corp. (the “Company”) issued a press release regarding the lawsuit described in Item 8.01 of this Current Report on Form 8-K; a copy of such press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated in this Item 7.01 by reference. The information included in this Item 7.01 and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.


ITEM 8.01     Other Events.


On September 28, 2018, the United States Securities and Exchange Commission filed a lawsuit in the United States District Court for the Eastern District of New York against the Company and its CEO and Chairman Rik J. Deitsch, and a consultant to the company, Sean McManus, alleging violations of the Securities Act, the Exchange Act and rules promulgated thereunder.


ITEM 9.01     Financial Statements and Exhibits.


Exhibit No.

 

Description

99.1

 

Press Release of the Company dated September 28, 2018



SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



Date: September 28, 2018

NUTRA PHARMA CORP.

 

By:

/s/ Rik J. Deitsch

 

 

Name:  

Rik J. Deitsch

 

 

Title:  

Chief Executive Officer/Director



EXHIBIT INDEX


Exhibit No.

 

Description

99.1

 

Press Release of the Company dated September 28, 2018





Nutra Pharma (CE) (USOTC:NPHC)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more Nutra Pharma (CE) Charts.
Nutra Pharma (CE) (USOTC:NPHC)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more Nutra Pharma (CE) Charts.